Taysha Gene Therapies, Inc. (TSHA) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
TSHA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TSHA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 88.3% | -1130.6% | -1115.3% |
| 2024 | 100.0% | -1097.6% | -1071.6% |
| 2023 | 100.0% | -468.8% | -722.1% |
| 2022 | 0.6% | -5037.1% | -6635.3% |
| 2021 | - | - | - |
Download Data
Export TSHA earnings history in CSV or JSON format
Free sign-in required to download data
Taysha Gene Therapies, Inc. (TSHA) Earnings Overview
As of May 8, 2026, Taysha Gene Therapies, Inc. (TSHA) reported trailing twelve-month net income of -$130M, reflecting +5.6% year-over-year growth. The company earned $-0.35 per diluted share over the past four quarters, with a net profit margin of -1115.3%.
Looking at the long-term picture, TSHA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2019.
Taysha Gene Therapies, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), TSHA has room to improve margins relative to the peer group. Compare TSHA vs SRPT →
TSHA Earnings vs Peers
Earnings metrics vs comparable public companies
TSHA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$109M | -22.1% | -$110M | $-0.34 | -1115.3% | -1130.6% |
| 2024 | -$89M | +20.0% | -$91M | $-0.36 | -1071.6% | -1097.6% |
| 2023 | -$112M | +32.8% | -$72M | $-0.96 | -722.1% | -468.8% |
| 2022 | -$166M | +4.9% | -$126M | $-3.78 | -6635.3% | -5037.1% |
| 2021 | -$175M | -305.9% | -$173M | $-4.64 | - | - |
| 2020 | -$43M | -3756.5% | -$43M | $-3.40 | - | - |
| 2019 | -$1M | - | -$1M | $-0.03 | - | - |
See TSHA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TSHA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TSHA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTSHA — Frequently Asked Questions
Quick answers to the most common questions about buying TSHA stock.
Is TSHA growing earnings?
TSHA EPS stands at $-0.35, with +5.6% growth matching the 5-year CAGR of N/A. TTM net income is $-130M. Earnings trajectory remains consistent.
What are TSHA's profit margins?
Taysha Gene Therapies, Inc. net margin is -1115.3%, with operating margin at -1130.6%. Below-average margins reflect competitive or cost pressures.
How consistent are TSHA's earnings?
TSHA earnings data spans 2019-2025. The current earnings trend is +5.6% YoY. Historical data enables comparison across business cycles.